WP
Woodline Partners Portfolio holdings
AUM
$18.9B
1-Year Return
23.37%
This Quarter Return
+9.42%
1 Year Return
+23.37%
3 Year Return
+125.78%
5 Year Return
+185.63%
10 Year Return
–
AUM
$11.8B
AUM Growth
+$1.41B
(+13%)
Cap. Flow
+$896M
Cap. Flow
% of AUM
7.57%
Top 10 Holdings %
Top 10 Hldgs %
12.15%
Holding
744
New
202
Increased
220
Reduced
152
Closed
160
Top Buys
| 1 |
ASML
ASML
|
$125M |
| 2 |
Meta Platforms (Facebook)
META
|
$100M |
| 3 |
STMicroelectronics
STM
|
$92.5M |
| 4 |
MetLife
MET
|
$79.4M |
| 5 |
Gilead Sciences
GILD
|
$77.3M |
Top Sells
| 1 |
TE Connectivity
TEL
|
$161M |
| 2 |
Eli Lilly
LLY
|
$151M |
| 3 |
Marsh & McLennan
MMC
|
$123M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
$86.7M |
| 5 |
Electronic Arts
EA
|
$78.6M |
Sector Composition
| 1 | Healthcare | 43.57% |
| 2 | Technology | 17.47% |
| 3 | Industrials | 8.1% |
| 4 | Energy | 6.42% |
| 5 | Financials | 6.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
176
Roper Technologies
ROP
$55.8B
| $22.6M | 0.19% |
+40,579
| New | +$22.6M |
|
177
Vontier
VNT
$6.37B
| $22.5M | 0.19% |
667,960
+335,976
| +101% | +$11.3M |
|
|
AVDL
178
Avadel Pharmaceuticals
AVDL
$1.53B
| $22.1M | 0.19% |
1,687,313
+182,781
| +12% | +$2.4M |
|
179
UDR
UDR
$13B
| $21.9M | 0.18% |
+483,300
| New | +$21.9M |
|
180
Estee Lauder
EL
$32.1B
| $21.8M | 0.18% |
218,955
+8,628
| +4% | +$860K |
|
181
Intapp
INTA
$3.67B
| $21.7M | 0.18% |
454,111
+102,088
| +29% | +$4.88M |
|
182
CAVA Group
CAVA
$7.73B
| $21.5M | 0.18% |
173,784
-213,913
| -55% | -$26.5M |
|
183
ICU Medical
ICUI
$3.24B
| $21.3M | 0.18% |
116,939
-66,369
| -36% | -$12.1M |
|
184
Ball Corp
BALL
$13.9B
| $21.2M | 0.18% |
312,261
-77,738
| -20% | -$5.28M |
|
185
Protagonist Therapeutics
PTGX
$3.77B
| $21M | 0.18% |
466,518
-355,655
| -43% | -$16M |
|
|
PETQ
186
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $20.9M | 0.18% |
+680,000
| New | +$20.9M |
|
187
Alkermes
ALKS
$4.94B
| $20.8M | 0.17% |
741,680
-329,391
| -31% | -$9.22M |
|
188
Enliven Therapeutics
ELVN
$1.19B
| $20.6M | 0.17% |
806,187
+83,683
| +12% | +$2.14M |
|
189
Annexon
ANNX
$238M
| $20.3M | 0.17% |
3,430,160
-641,517
| -16% | -$3.8M |
|
190
Soleno Therapeutics
SLNO
$3.71B
| $20.3M | 0.17% |
402,083
+82,878
| +26% | +$4.18M |
|
191
Marvell Technology
MRVL
$54.6B
| $20.2M | 0.17% |
280,483
-298,840
| -52% | -$21.6M |
|
192
Bentley Systems
BSY
$16.3B
| $19.9M | 0.17% |
+392,336
| New | +$19.9M |
|
193
New York Times
NYT
$9.6B
| $19.9M | 0.17% |
357,765
-12,181
| -3% | -$678K |
|
194
Align Technology
ALGN
$10.1B
| $19.7M | 0.17% |
+77,415
| New | +$19.7M |
|
195
NewAmsterdam Pharma
NAMS
$3.04B
| $19.3M | 0.16% |
1,164,677
+681,289
| +141% | +$11.3M |
|
196
Idexx Laboratories
IDXX
$51.4B
| $19.2M | 0.16% |
+37,919
| New | +$19.2M |
|
|
HES
197
DELISTED
Hess
HES
| $19M | 0.16% |
140,072
-19,999
| -12% | -$2.72M |
|
198
Teva Pharmaceuticals
TEVA
$21.7B
| $18.9M | 0.16% |
1,047,553
| – | – |
|
199
Trip.com Group
TCOM
$47.6B
| $18.7M | 0.16% |
314,054
-110,209
| -26% | -$6.55M |
|
|
CRGX
200
DELISTED
CARGO Therapeutics
CRGX
| $18.7M | 0.16% |
+1,011,475
| New | +$18.7M |
|